Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Phase 3

Completed

Conditions: Multiple Sclerosis

Registration Number: NCT00648908

Lead Sponsor: Acorda Therapeutics

Brief Summary: The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who previously participated in Acorda Therapeutics Protocol MS-F203.

Detailed Description: Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 269

Inclusion Criteria

subject must have been previously enrolled in Acorda Therapeutics MS-F203 study for multiple sclerosis and received either Fampridine-SR or placebo
subject is a man or woman with clinical definite multiple sclerosis as defined by McDonald (McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis; Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis; Annals of Neurology. 2001; 50: 121-127)
subject must be at least 18 years of age. Any subject who is now over the age of 70 must be in good overall health in the judgment of the Investigator
subject must be of adequate cognitive function, as judged by the Investigator, to understand and sign the IRB/REB-approved informed consent form prior to the performance of any study-specific procedures and is willing to comply with the required scheduling and assessments of the protocol
subjects who are women of childbearing potential, regardless of sexual activity, must have a negative urine pregnancy test at the Screening Visit.

Exclusion Criteria

women who are either pregnant or breastfeeding, and women of childbearing potential (defined as not surgically sterile or at least two years post menopausal) who are engaged in active heterosexual relations and, are not using one of the following birth control methods: tubal ligation, implantable contraception device, oral, patch, injectable or transdermal contraceptive, barrier method or sexual activity restricted to vasectomized partner.
subject discontinued prematurely from the MS-F203 study
subject has a history of seizures or has evidence of past, or possible, epileptiform activity on an EEG
subject has either a clinically significant abnormal ECG or laboratory value(s) at the Screening visit, as judged by the Investigator that would preclude entry into the study. ECG and laboratory results from Visit 6 or repeat results from Visit 7 of the MS-F203 study may be used as the baseline for the current study
subject has angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator
subject has a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet (hydroxypropyl methylcellulose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, opadry white (tablet film coating))
subject has received an investigational drug, except for Fampridine-SR or matching placebo under protocol MS-F203, within 30 days of the Screening Visit. Subject is scheduled to enroll in an investigational drug trial at any time during this study.
subject has a history of drug or alcohol abuse within the past year

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Summary of Treatment Emergent Adverse Events (TEAE).	up to 5 years	All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.

Secondary Outcome Measures

Name	Time	Method
Timed 25 Foot Walk (T25FW)	Week 2, 14, 26, continuing every 26 weeks until the Final Visit
Subject Global Impression (SGI)	visit 1 and every clinic visit	Patients asked to complete a Subject Impression questionnaire rating his/her impression of the effects of study drug during the preceding week, specifically in regards to signs and symptoms associated with Multiple Sclerosis (MS). For the SGI, the potential responses to the effects of the investigational drug during the preceding week were 1=terrible, 2=unhappy, 3=mostly dissatisfied, 4=neutral/ mixed, 5=mostly satisfied, 6=pleased, and 7=delighted.
Clinician Global Impression of Change (CGIC)	visit 1 and every clinic visit	Investigator's overall impression of the patients neurological status and general state of health related to his/her participation in the study; specifically signs and symptoms associated with MS. The potential responses were 1=very much improved, 2=much improved, 3=somewhat improved, 4=no change, 5=somewhat worse, 6=much worse, and 7=very much worse.
Expanded Disability Status Scale (EDSS)	Screening visit, visit 6 and every 24 months thereafter	Each patient, based on their baseline neurological exam, are scored according to the EDSS The EDSS was used to grade patient disability on a scale from 0.0 (normal neurological exam) to 10.0 (death) at the Screening Visit, Visit 6, and Final Visit or Early Termination Visit if applicable.

Trial Locations

Locations (32): Advanced Neurology Specialists
🇺🇸
Great Falls, Montana, United States
Ohio State University MS Center
🇺🇸
Columbus, Ohio, United States
University of Texas-Houston
🇺🇸
Houston, Texas, United States
University of Chicago
🇺🇸
Chicago, Illinois, United States
USC, Keck School of Medicine Health Care Consultation Center
🇺🇸
Los Angeles, California, United States
Corinne Goldsmith Dickinson Center for MS
🇺🇸
New York, New York, United States
Shepherd Center
🇺🇸
Atlanta, Georgia, United States
University of Rochester
🇺🇸
Rochester, New York, United States
Foothills Medical Center
🇨🇦
Calgary, Alberta, Canada
Wayne State University, Department of Neurology
🇺🇸
Detroit, Michigan, United States
University of British Columbia, Vancouver Coastal Health Research Institute
🇨🇦
Vancouver, British Columbia, Canada
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
🇺🇸
Phoenix, Arizona, United States
Indiana University MS Center
🇺🇸
Indianapolis, Indiana, United States
Maryland Center for MS
🇺🇸
Baltimore, Maryland, United States
The Schapiro Center for MS
🇺🇸
Golden Valley, Minnesota, United States
Washington University School of Medicine, Div. of Rehab/Neurology
🇺🇸
St. Louis, Missouri, United States
Gimbel MS Center at Holy Name Hospital
🇺🇸
Teaneck, New Jersey, United States
Maimonides MS Care Center
🇺🇸
Brooklyn, New York, United States
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
CMC - Neuroscience & Spine Institute, Division of Neurology
🇺🇸
Charlotte, North Carolina, United States
Raleigh Neurology Associates
🇺🇸
Raleigh, North Carolina, United States
Neurological Research Center, Inc.
🇺🇸
Bennington, Vermont, United States
Thomas Jefferson University Physicians
🇺🇸
Philadelphia, Pennsylvania, United States
Fletcher Allen Health Care
🇺🇸
Burlington, Vermont, United States
Allegheny General Hospital, Allegheny Neurological Associates
🇺🇸
Pittsburgh, Pennsylvania, United States
MS Center at Evergreen
🇺🇸
Kirkland, Washington, United States
River Valley Health c/o Stan Cassidy Centre for Rehabilitation
🇨🇦
Fredericton, New Brunswick, Canada
QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site
🇨🇦
Halifax, Nova Scotia, Canada
Ottawa Hospital General Campus
🇨🇦
Ottawa, Ontario, Canada
SUNY Stony Brook
🇺🇸
Stony Brook, New York, United States
Oregon Health & Science University, MS Center of Oregon, UHS-42
🇺🇸
Portland, Oregon, United States
UC Davis
🇺🇸
Sacramento, California, United States